ISRCTN46778796 https://doi.org/10.1186/ISRCTN46778796

Randomised Comparison of Cyclical Anthracycline-Based Chemotherapy [PA(BI)OE] with Alternating Chemotherapy [ChlVPP /PABIOE] in Advanced Hodgkin's Disease

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 29/10/2019	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

LY2

Study information

Scientific Title
Randomised Comparison of Cyclical Anthracycline-Based Chemotherapy [PA(BI)OE] with Alternating Chemotherapy [ChlVPP/PABIOE] in Advanced Hodgkin's Disease

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Lymphoma (Hodgkin's)

Interventions
1. PA(BI)OE Regimen: Multi-drug chemotherapy with adriamycin, vincristine, prednisolone, etoposide and bleomycin [PA(BI)OE] cycle repeated every 21 days. A minimum of six courses to be given with at least two following documentation of clinical complete remission and a maximum of eight courses. Bleomycin to be given for the first four courses only.

2. ChlVPP/PABIOE Regimen: Multi-drug chemotherapy with chlorambucil, procarbazine, prednisolone and vinblastine (ChlVPP) alternating every 21 days with PABIOE.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Cancer drug

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1990

Completion date
30/04/1996

Eligibility

Key inclusion criteria
1. All previously untreated and properly staged patients aged between 15 and 69 years (inclusive) with Hodgkin's disease for whom chemotherapy is indicated are eligible for this trial, ie Stage I & IIA (poor prognosis), IB, IIB, III, IV
2. Patients must be free from any irreversible medical condition that would drastically limit their life span or prohibit the use of combination chemotherapy. This applies particularly to elderly patients
3. Adequate long term follow-up must be possible

Participant type(s)
Patient

Age group
Adult

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1990

Date of final enrolment
30/04/1996

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
British National Lymphoma Investigation (BNLI) (UK)

Sponsor details
CRC and UCL Cancer Trials Centre
222 Euston Road
London
United Kingdom
NW1 2DA
+44 (0)20 7679 8060
bnli@ctc.ucl.ac.uk

Sponsor type
Charity

Website
http://www.bnli.ucl.ac.uk

Funder(s)

Funder type
Research organisation

Funder Name
British National Lymphoma Investigation, Central Lymphoma Group (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration